Caprock Group LLC Takes $2.09 Million Position in Humana Inc. $HUM

Caprock Group LLC acquired a new stake in shares of Humana Inc. (NYSE:HUM) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 8,046 shares of the insurance provider’s stock, valued at approximately $2,093,000.

Other hedge funds have also bought and sold shares of the company. Elevation Point Wealth Partners LLC purchased a new stake in shares of Humana during the 2nd quarter valued at about $32,000. Mather Group LLC. bought a new position in Humana during the third quarter valued at approximately $34,000. AlphaCore Capital LLC purchased a new stake in Humana in the second quarter worth approximately $39,000. Private Wealth Management Group LLC grew its position in Humana by 47.5% in the 3rd quarter. Private Wealth Management Group LLC now owns 149 shares of the insurance provider’s stock worth $39,000 after purchasing an additional 48 shares during the period. Finally, SJS Investment Consulting Inc. raised its stake in Humana by 19,300.0% during the 3rd quarter. SJS Investment Consulting Inc. now owns 194 shares of the insurance provider’s stock valued at $50,000 after buying an additional 193 shares during the last quarter. Hedge funds and other institutional investors own 92.38% of the company’s stock.

Humana Stock Performance

HUM opened at $183.92 on Friday. The company has a 50 day simple moving average of $244.65 and a two-hundred day simple moving average of $260.85. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.00 and a quick ratio of 2.02. The firm has a market cap of $22.12 billion, a P/E ratio of 18.73, a PEG ratio of 1.99 and a beta of 0.44. Humana Inc. has a 1-year low of $169.61 and a 1-year high of $315.35.

Humana (NYSE:HUM) last released its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. Humana had a net margin of 0.92% and a return on equity of 11.43%. The company had revenue of $32.64 billion for the quarter, compared to analysts’ expectations of $32.08 billion. During the same quarter in the previous year, the company earned ($2.16) EPS. Humana’s revenue for the quarter was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. Equities analysts forecast that Humana Inc. will post 16.47 earnings per share for the current fiscal year.

More Humana News

Here are the key news stories impacting Humana this week:

• Positive Sentiment: CenterWell (Humana’s healthcare services unit) closed the acquisition of MaxHealth, adding a sizable Florida primary‑care network (~82 owned/affiliated clinics and >80,000 patients in value‑based programs) which expands Humana’s senior-focused, value‑based primary care footprint and accelerates revenue and membership growth in higher-value care. CenterWell Completes Acquisition of MaxHealth
• Positive Sentiment: Management signals more primary‑care deals may be coming (CEO remarks and media reports about a potential ~$1B strategic push), reinforcing the company’s strategy to grow value‑based care capacity — a long‑term growth catalyst if Humana can scale clinics and convert MA members to higher‑margin care. Humana CEO hints at upcoming primary care deal
• Neutral Sentiment: Jefferies cut its price target (from $310 to $235) but kept a Buy rating, reflecting disagreement among analysts on Humana’s growth vs. margin tradeoff — some firms still see upside despite lower near‑term earnings visibility. Jefferies price target change
• Negative Sentiment: Several major analysts materially lowered price targets and trimmed estimates (TD Cowen to $173 Hold; JPMorgan to $180 Neutral; Evercore, Cantor, Leerink also cut targets), reflecting concern that Medicare Advantage cost pressures, lower quality (STAR) ratings, and a cautious 2026 earnings guide will weigh on near‑term profitability. TD Cowen PT cut
• Negative Sentiment: Humana reported a fourth‑quarter loss and issued a cautious 2026 outlook (management flagged sharply lower near‑term earnings as Medicare Advantage membership surges but margins remain under pressure), which prompted analysts to slash forecasts and is the primary fundamental reason for downward pressure on the stock. Humana stock falls on disappointing earnings forecast

Analysts Set New Price Targets

Several analysts recently commented on HUM shares. Leerink Partners cut their price objective on Humana from $267.00 to $185.00 and set a “market perform” rating for the company in a report on Thursday. Wolfe Research raised their target price on Humana from $300.00 to $325.00 and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Truist Financial reduced their price target on shares of Humana from $300.00 to $285.00 and set a “hold” rating for the company in a research report on Monday, November 10th. KeyCorp reissued a “sector weight” rating on shares of Humana in a report on Friday, December 12th. Finally, Sanford C. Bernstein reaffirmed an “outperform” rating and set a $344.00 target price on shares of Humana in a report on Tuesday, January 6th. Seven equities research analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and five have assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $239.46.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.